6325-58-2

Usage

Uses

Used in Organic Synthesis:
[(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)sulfanyl]acetic acid is used as a building block for the synthesis of various organic compounds due to its versatile chemical structure and functional groups.
Used in Medicinal Chemistry:
[(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)sulfanyl]acetic acid is used as a starting material for the development of new pharmaceutical agents, leveraging its unique structure and properties to potentially create novel therapeutics.
Used in Pharmaceutical Development:
In the pharmaceutical industry, [(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)sulfanyl]acetic acid is used as a precursor for the synthesis of new drug candidates, aiming to explore its potential in treating various diseases and conditions.
Further research and exploration of the chemical reactivity and biological activity of [(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)sulfanyl]acetic acid may reveal additional applications in different industries, such as materials science or environmental chemistry.

Upstream product

• 58-27-5 menadione 
• 856197-80-3 2,6,7-tribromo-3-methyl-5,6,7,8-tetrahydro-naphthalene-1,4-diol 
• 859997-89-0 2-bromo-3-methyl-5,8-dihydro-[1,4]naphthoquinone 
• 3090-46-8 2-methyl-5,8-dihydro-1,4-naphthalenediol 
• 3129-39-3 2-bromo-3-methyl-[1,4]naphthoquinone 
• 68-11-1 mercaptoacetic acid 

Downstream Products

• 58-27-5 menadione 

Relevant academic research and scientific papers

Characterization of molecular complexes of 1,4-naphthoquinone derivatives

The structures of sulphur atom tethered quinone containing flexible carboxylic acid (3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-ylsulfanyl)acetic acid (1) and its molecular complex with 4,4′-bipyridine (3) are determined. The compound 1 crystallizes in P-1 (triclinic, a = 7.5378(6) A, b = 7.6413(7) A, c = 10.3101(9) A; α = 89.779 (7)°, β = 81.042 (5)°, γ = 89.101(7)°) and the molecular complex 3 crystallises in P2(1)/n (monoclinic, a = 9.3383(7) A, b = 3.970(3) A, c = 42.130(3) A, β = 91.056(5)°) space groups, respectively. The R 2 2 (8) type hydrogen bonding between dicarboxylic acid groups present in the parent compound 1 is lost on interaction with 4, 4′-bipyridine; in the molecular complex 3 R 2 2 (7) type of O???H-C and O-H???N interactions are present between the pyridine rings and carboxylic acid groups. The molecular complex (4) derived from 3-carboxymethylsulfanyl-1,4- dihydroxynaphthalen-2-yl-sulfanyl) acetic acid (2) with triphenylphosphine oxide in 1:2 ratio, crystallises in C2/c space group have monoclinic, a = 26.0494(13) A, b = 10.5402(5) A, c = 17.1023(8) A, β = 108.719 (5)°). The triphenylphosphine oxide molecules are preferentially held by O-H???O interactions between carboxylic acid and P=O bond.

Synthesis and SAR study of novel anticancer and antimicrobial naphthoquinone amide derivatives

A series of novel naphthoquinone amide derivatives of the bioactive quinones, plumbagin, juglone, menadione and lawsone, with various amino acids were synthesized. The compounds were characterized by 1H NMR, 13C NMR, Mass, IR and ele

Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity

CDC25 dual-specificity phosphatases are essential key regulators of eukaryotic cell cycle progression and the CDC25A and B isoforms are over-expressed in different tumors and related cancer cell lines. CDC25s are now considered to be interesting targets in the search for novel anticancer agents. We describe new compounds derived from vitamin K3 that inhibit CDC25B activity with IC50 values in the low micromolar range. These naphthoquinone derivatives also display antiproliferative activity on HeLa cells as expected for CDC25 inhibitors and inhibit cell growth in a clonogenic assay at submicromolar concentrations. They increase inhibitory tyrosine 15 phosphorylation of CDK and induce the cleavage of PARP, a hallmark of apoptosis.